AXSM
Axsome Therapeutics, Inc. NASDAQ$206.53
Mkt Cap $10.3B
52w Low $96.09
91.3% of range
52w High $217.00
50d MA $170.84
200d MA $146.60
P/E (TTM)
-56.1x
EV/EBITDA
-53.6x
P/B
116.4x
Debt/Equity
2.7x
ROE
-207.5%
P/FCF
-96.8x
RSI (14)
—
ATR (14)
—
Beta
0.47
50d MA
$170.84
200d MA
$146.60
Avg Volume
592.4K
About
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as w…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | AMC | -0.70 | -0.71 | -1.4% | 174.76 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% | -7.4% | — |
| Nov 3, 2025 | AMC | -0.82 | -0.94 | -14.6% | 135.75 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% | +8.9% | — |
| Aug 4, 2025 | AMC | -1.00 | -0.92 | +8.0% | 106.54 | -0.4% | -2.8% | -3.1% | -2.1% | -1.6% | -2.4% | +14.5% | — |
| May 5, 2025 | AMC | -1.26 | -0.80 | +36.5% | 116.49 | -0.6% | -3.7% | -4.8% | -6.5% | -7.5% | -5.4% | -7.2% | — |
| Feb 18, 2025 | AMC | -1.00 | -0.96 | +4.0% | 128.09 | +0.6% | -0.9% | +0.8% | +7.5% | +2.1% | -0.8% | -1.4% | — |
| Nov 12, 2024 | AMC | -1.38 | -1.34 | +2.9% | 99.49 | -0.5% | -1.7% | -2.1% | -6.4% | -7.1% | -4.1% | -5.1% | — |
| Aug 5, 2024 | AMC | -1.30 | -1.24 | +4.6% | 83.21 | +1.8% | +2.8% | +0.8% | +2.2% | -0.1% | +2.1% | +14.8% | — |
| May 6, 2024 | AMC | -1.20 | -1.09 | +9.2% | 75.94 | -0.5% | +1.3% | -0.3% | -3.0% | -4.5% | -0.4% | -2.4% | — |
| Feb 20, 2024 | AMC | -1.21 | -0.73 | +39.7% | 81.14 | -0.1% | +1.2% | -0.8% | -2.7% | +1.4% | +3.5% | -0.3% | — |
| Nov 6, 2023 | AMC | -1.24 | -1.32 | -6.5% | 62.42 | -1.1% | +1.1% | -1.4% | -3.8% | -8.0% | -5.0% | +11.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Needham | Maintains | Buy → Buy | — | $207.75 | $207.23 | -0.3% | -0.6% | — | — | — | — |
| Apr 10 | UBS | Maintains | Buy → Buy | — | $178.90 | $181.00 | +1.2% | -0.4% | -0.3% | +3.0% | +3.0% | +3.0% |
| Mar 25 | Guggenheim | Maintains | Buy → Buy | — | $158.75 | $160.74 | +1.3% | +1.9% | +3.5% | -1.5% | +1.1% | +6.5% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 24 | RBC Capital | Maintains | Outperform → Outperform | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 24 | UBS | Maintains | Buy → Buy | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $183.72 | $176.42 | -4.0% | -4.9% | -7.5% | -10.6% | -11.2% | -10.8% |
| Feb 3 | Jefferies | Maintains | Buy → Buy | — | $185.88 | $188.25 | +1.3% | +0.8% | -0.2% | -2.7% | -1.8% | -1.4% |
| Jan 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $188.02 | $187.69 | -0.2% | -1.5% | -1.5% | -2.0% | -1.1% | -0.4% |
Recent Filings
8-K · 2.02
!! High
Axsome Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Axsome Therapeutics reported quarterly earnings results; investors should review the attached press release for detailed financial performance and operational metrics.
May 4
8-K · 8.01
!! High
Axsome Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
FDA approval of Axsome's AUVELITY for Alzheimer's dementia-related agitation expands the company's commercial opportunity in neurology and validates its therapeutic approach for this patient population.
Apr 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Axsome is acquiring TAK-063, an oral PDE10A inhibitor with potential in neuropsychiatric disorders, expanding its CNS pipeline and diversifying its portfolio beyond current offerings.
Apr 1
8-K
Axsome Therapeutics, Inc -- 8-K Filing
Axsome Therapeutics reported 2025 financial results and provided a business update, with the filing signed by CEO Herriot Tabuteau on February 23, 2026.
Feb 23
8-K · 8.01
!! High
Axsome Therapeutics, Inc -- 8-K 8.01: Material Event / Announcement
Axsome Therapeutics resolved patent litigation with Alkem regarding SUNOSI, eliminating a legal threat to the drug's market exclusivity in the United States.
Feb 17
Data updated apr 24, 2026 8:15pm
· Source: massive.com